Rocket Pharmaceuticals Historical PE Ratio
This RCKT historical PE ratio page, which was last updated 11/3/2026, presents historical price to earnings information for Rocket Pharmaceuticals under both the TTM method and
the annualized method, and presented in both tabular and graphical format for ease of study.
RCKT Historical PE Ratio Notes
— Rocket Pharmaceuticals (NASDAQ: RCKT) is a clinical-stage biotechnology company focused on developing gene therapies for rare and devastating diseases, particularly those with significant unmet medical needs. The company's pipeline targets both pediatric and adult genetic disorders, such as Danon disease, Fanconi anemia, Leukocyte Adhesion Deficiency-I (LAD-I), and Pyruvate Kinase Deficiency (PKD). As an investor researching RCKT's historical price-earnings (PE) ratio, it's essential to understand that companies like Rocket, which are in early-stage clinical development and do not yet generate commercial revenue, typically report negative earnings due to significant R&D investments. This often means that the historical PE ratio is either not meaningful or not calculated (shown as ȁcN/Aȁd in charts & tables), since there are no positive earnings to compare against the stock price. During clinics & regulatory milestones, the share price may move substantially even as earnings remain negative, leading to pronounced volatility in PE ratios or their absence altogether. When analyzing RCKT's historical PE ratio, focus should be placed on pipeline progress, clinical trial outcomes &, market expectations for future commercial viability, rather than traditional valuation metrics that apply to mature, profitable companies.
How should the RCKT historical PE ratio be determined?
Realizing that PE stands for Price to Earnings ratio, we need two values to compute it: stock price and earnings per share. The stock price at any given date is a known historical value, but what about the earnings number to use?
✔️Accepted answer:
There are a number of different approaches when it comes to calculating a historical PE ratio for a company like Rocket Pharmaceuticals. We like to take our measurements on each of the past quarterly earnings reports. That only leaves the question of whether the earnings number at that quarterly report should be used on an annualized basis, or some other method. We approach this question using three different methods, on this RCKT Historical PE Ratio page.
What is the average historical PE for RCKT based on annualized quarterly earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use that quarter's earnings result annualized?
✔️Accepted answer:
The RCKT historical PE ratio using the annualized quarterly earnings method works out to NA.
What is the average historical PE for RCKT based on trailing twelve month earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use the trailing twelve months combined earnings result in the calculation?
✔️Accepted answer:
The RCKT historical PE ratio using the TTM earnings method works out to NA.
On this page we presented the
RCKT Historical PE Ratio information for Rocket Pharmaceuticals' stock.
The average RCKT historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average RCKT historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.
Let's now compare this RCKT historical PE result, against the recent PE: when this page was posted on 11/2/2026, the most recent closing price for RCKT had been 2.47, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.
For self directed investors doing their due diligence on RCKT or any other given stock, valuation analysis for RCKT
can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis
as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.
That's why we bring you
HistoricalPERatio.com to make it easy for investors to investigate
Rocket Pharmaceuticals PE history or the past PE information for any stock in our coverage universe.
And in your continued research we hope you will be sure to check out the further links included for earnings
surprises history (beat/miss data) as well as next earnings dates for RCKT. Thanks for visiting, and the next
time you need to research
RCKT Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your
go-to historical PE ratio research resource of choice.